• Microbiology and Biotechnology Letters
• /
• v.42 no.4
• /
• pp.354-360
• /
• 2014

In this study, the anti-obesity activity of Smilax china methanol extract (SCME) was evaluated using a pancreatic lipase enzyme inhibition assay, and a cell culture model system. Results indicated that, SCME effectively inhibited pancreatic lipase enzyme activity in a dose-dependent manner. Furthermore, SCME significantly suppressed insulin, dexamethasone, 3-isobutyl-1-methylxanthine-induced adipocyte differentiation, lipid accumulation, and triglyceride contents on 3T3-L1 preadipocytes, in a dose-dependent manner. The anti-adipogenic effect was modulated by cytidine-cytidine-adenosine-adenosine-thymidine (CCAAT)/enhancer binding proteins (C/EBP) ${\alpha}$, $C/EBP{\beta}$, and the peroxisome proliferator-activated receptor ${\gamma}$ gene and protein expressions. Moreover, SCME triggered lipolysis effects dose-dependently on adipocyte. Taken together, these results provide an important new insight into SCME, indicating that it possesses anti-obesity activity through pancreatic lipase inhibition, anti-adipogenic and lipolysis effects. SCME may therefore be utilized as a promising source in the field of nutraceuticals. The identification of active compounds that confer the anti-obesity activities of SCME may be a logical next step.

• Journal of Life Science
• /
• v.27 no.6
• /
• pp.680-687
• /
• 2017

Recently, there has been a marked increase in the use of bioactive products resulting from the fermentation of natural substances by microorganisms. In this study, Opuntia humifusa (OH) was fermented using Lactobacillus plantarum (fermented Opuntia humifusa; fOH). We then examined the anti-obesity effect of fOH in mice fed a 45% Kcal high fat diet (HFD). In this study, mice were treated with fOH concentrations of 100, 200, and 400 mg/kg. The mice in the control group were treated with OH at a concentration of 400 mg/kg based on previous animal experiments. All of the mice given a continuous HFD showed an increase in their weight, the density of abdominal fat, and the accumulated periovaric and abdominal fat. All of these obesity-linked factors, however, were significantly decreased in the groups treated with fOH at concentrations of 200 and 400 mg/kg. Mice treated with fOH at 100 mg/kg did not show a significant decrease in these obesity-linked factors compared to the control group. It appears that fOH fermented by L. plantarum has a greater anti-obesity effect in HFD-supplied mice compared to unfermented OH. While further studies of fOH are needed to examine its effect on obesity, hyperlipidemia, hepatic steatosis, renal function, and type II diabetes with its relevant complications, fOH may have significant therapeutic potential in the treatment of metabolic syndrome.

• Journal of Physiology & Pathology in Korean Medicine
• /
• v.32 no.6
• /
• pp.384-395
• /
• 2018

The aim of this study was to investigate whether a novel formulation of an herbal extracts has an inhibitory effect on obesity. To determine its anti-obesity effects, we performed anti-obesity-related experiments in vitro and in vivo. Thus, our present study was carried out to evaluate the anti-obesity effect of herbal extracts using a high fat diet (HFD)-induced obese mouse model and 3T3-L1 adipose cells. The effects of each herbal extracts on lipid accumulation in 3T3-L1 cells were examined using Oil Red O staining. Results showed that treatment with each herbal extracts at $10{\sim}100{\mu}g/ml$ had no effect on cell morphology and viability. Without evidence of toxicity, herbal extracts treatment decreased lipid accumulation compared with the untreated adipocytes controls as shown by the lower absorbance of Oil Red O stain. Futhermore, compared with control-differentiated mature adipocytes, each herbal extracts significantly inhibited lipid accumulation in mature 3T3-L1 adipocytes. In the HFD-fed obese mice, body weight, liver weight and white adipose tissue weights were significantly reduced by mixture of herbal extracts administration in mouse skin. Futhermore, we found that mixture of herbal extracts administration suppressed serum triglyceride (TG), and total cholesterol (TCHO) in HFD-induced obese mouse model. The mixture of herbal extracts of permeability was estimated by measuring the transepithelial electrical resistance (TEER) value in pig skin. The optimized formulations of herbal extracts (Test 3 formulation) showed skin permeation. However, test 1 formulation containing essential oil as enhancer showed maximum skin permeation. After confirming the enhanced skin permeability, in vivo studies were performed to assess whether skin irritation potential on the basis of a primary irritation index (PII) in rabbit skin. Reactions were scored for erythema/edema reactions at 24 h, 48 h and 72 h post-application. It was concluded that the test 1 formulation was not irritation (PII = 0). The present study suggests that the test 1 formulation might be of therapeutic interest with respect to the treatment of obesity.

• The Korea Journal of Herbology
• /
• v.33 no.2
• /
• pp.59-67
• /
• 2018

Objective : Plantago asiatica L. has been used for many years in Korea, China, and Japan for the treatment of many diseases such as anti-inflammatory, anti-asthma and diuretic. But the anti-obesity effect of Plantaginis asiaticae Folium has not been studied yet. Thus, this study aimed to demonstrate the anti-obesity efficacy of Plantaginis asiaticae Folium water extract (PAF) in high fat diet-induced obesity animal model. Method : Male, five-weeks old C57BL/6 mice were divided into 5 groups; ND (normal diet + 0.9% saline), HFD (high-fat diet + 0.9% saline), PC (high-fat diet + Garcinia cambogia 500 mg/kg), PAF 100, 300 (high-fat diet + PAF 100, 300 mg/kg. Treatments were performed daily for 6 weeks per os. We evaluated the changes of body weight, white adipose tissues weight, hepatic and fecal lipids level, pancreatic lipase activity and lipid profiles in plasma. Result : Body weights, adipose tissue weights and FER were significantly lower in mice fed the high-fat diet with PAF treatment than in mice fed the high-fat diet alone. In plasma, TG, TC, LDL-C, ATS and ALT levels significantly decreased in PAF groups compared with HFD group. Also, hepatic triglyceride (TG) levels decreased and fecal TG increased in PAF groups compared to HFD group. In addition, the activity of pancreatic lipase was decreased in the PAF groups compared to that of HFD group. Conclusion: These results suggest PAF extract is effective in preventing and improvement obesity, so it might be a potential and safe material for anti-obesity agent of weight control or functional supplements.

• Journal of the Korean Applied Science and Technology
• /
• v.36 no.4
• /
• pp.1198-1207
• /
• 2019

This study investigated action mechanism and biological effect of Jijang-kimch, including its anti-obesity effect and blood lipid-decreasing effect in a high-fat diet-induced obese model animals. There were four treatment groups: CD (chow diet as normal control), HFD (high fat diet as obesity control), HFDCK (HFD plus commercial kimchi extracts), and HFDJK (HFD plus Jijang-kimchi extract). Kimchi extracts were orally administered for 28 days. Body weight, liver, and adipose tissue weight declined in HFDJK compared to those in HFDCK(p<0.05). Blood triglyceride, total cholesterol, low density lipoprotein-cholesterol (LDL-C), and glucose level decreased in CD, HFDJK, and HFDCK compared to those in HFD(p<0.05). Those in HFDJK were lower than those in HFDCK(p<0.05). Sizes of liver and adipose cells increased in HFD, HFDCK, and HFDJ that those in CD(p<0.05). Those in HFDJK were greatly decreased than those in HFDCK(p<0.05). These results indicate that ingestion of Jijang-kimchi in obese model animals has anti-obesity effect by lowering blood lipid and glucose levels and decreasing adipocyte size compared to that of commercial-kimchi.

• Food Science of Animal Resources
• /
• v.38 no.3
• /
• pp.554-569
• /
• 2018

This study aimed to investigate the physiological characteristics and anti-obesity effects of Lactobacillus plantarum K10. The ${\alpha}-amylase$ inhibitory activity, ${\alpha}-glucosidase$ inhibitory activity, and lipase inhibitory activity of L. plantarum K10 was $94.66{\pm}4.34%$, $99.78{\pm}0.12%$, and $87.40{\pm}1.41%$, respectively. Moreover, the strain inhibited the adipocyte differentiation of 3T3-L1 cells ($32.61{\pm}8.32%$) at a concentration of $100{\mu}g/mL$. In order to determine its potential for use as a probiotic, we investigated the physiological characteristics of L. plantarum K10. L. plantarum K10 was resistant to gentamycin, kanamycin, streptomycin, ampicillin, ciprofloxacin, tetracycline, vancomycin, and chloramphenicol. It also showed higher Leucine arylamidase, Valine arylamidase, and ${\beta}-galactosidase$ activities. Moreover, it was comparatively tolerant to bile juice and acid, exhibiting resistance to Escherichia coli, Salmonella Typhimurium, Listeria monocytogenes, and Staphylococcus aureus with rates of 90.71%, 11.86%, 14.19%, and 23.08%, respectively. The strain did not produce biogenic amines and showed higher adhesion to HT-29 cells compared to L. rhamnosus GG. As a result of the animal study, L. plantarum K10 showed significantly lower body weight compared to the high-fat diet group. The administration of L. plantarum K10 resulted in a reduction of subcutaneous fat mass and mesenteric fat mass compared to the high-fat diet (HFD) group. L. plantarum K10 also showed improvement in gut permeability compared to the HFD positive control group. These results demonstrate that L. plantarum K10 has potential as a probiotic with anti-obesity effects.

• Journal of Microbiology and Biotechnology
• /
• v.33 no.5
• /
• pp.621-633
• /
• 2023

We investigated the probiotic characteristics and anti-obesity effect of Lactiplantibacillus plantarum MGEL20154, a strain that possesses excellent intestinal adhesion and viability. The in vitro properties, e.g., gastrointestinal (GI) resistance, adhesion, and enzyme activity, demonstrated that MGEL20154 is a potential probiotic candidate. Oral administration of MGEL20154 to diet-induced obese C57BL/6J mice for 8 weeks resulted in a feed efficacy decrease by 44.7% compared to that of the high-fat diet (HFD) group. The reduction rate of weight gain was about 48.5% in the HFD+MGEL20154 group compared to that of the HFD group after 8 weeks, and the epididymal fat pad was also reduced in size by 25.2%. In addition, the upregulation of the zo-1, pparα, and erk2, and downregulation of the nf-κb and glut2 genes in Caco-2 cells by MGEL20154 were observed. Therefore, we propose that the anti-obesity effect of the strain is exerted by inhibiting carbohydrate absorption and regulating gene expression in the intestine.

• The Korean journal of internal medicine
• /
• v.33 no.6
• /
• pp.1210-1223
• /
• 2018

Background/Aims: The co-occurrence of obesity aggravates asthma symptoms. Diet-induced obesity increases helper T cell (TH) 17 cell differentiation in adipose tissue and the spleen. The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor pravastatin can potentially be used to treat asthma in obese patients by inhibiting interleukin 17 (IL-17) expression. This study investigated the combined effects of pravastatin and anti-IL-17 antibody treatment on allergic inflammation in a mouse model of obesity-related asthma. Methods: High-fat diet (HFD)-induced obesity was induced in C57BL/6 mice with or without ovalbumin (OVA) sensitization and challenge. Mice were administered the anti-IL-17 antibody, pravastatin, or both, and pathophysiological and immunological responses were analyzed. Results: HFD exacerbated allergic airway inflammation in the bronchoalveolar lavage fluid of HFD-OVA mice as compared to OVA mice. Blockading of the IL-17 in the HFD-OVA mice decreased airway hyper-responsiveness (AHR) and airway inflammation compared to the HFD-OVA mice. Moreover, the administration of the anti-IL-17 antibody decreased the leptin/adiponectin ratio in the HFD-OVA but not the OVA mice. Co-administration of pravastatin and anti-IL-17 inhibited airway inflammation and AHR, decreased goblet cell numbers, and increased adipokine levels in obese asthmatic mice. Conclusions: These results suggest that the IL-17-leptin/adiponectin axis plays a key role in airway inflammation in obesity-related asthma. Our findings suggest a potential new treatment for IL-17 as a target that may benefit obesity-related asthma patients who respond poorly to typical asthma medications.

• Journal of the Korean Society of Food Science and Nutrition
• /
• v.38 no.1
• /
• pp.32-38
• /
• 2009

In this study, we investigated the anti-obesity activity of the herbal extract mixture (HEM). The inhibitory effect of HEM on triglyceride accumulation of 3T3-L1 preadipocyte was examined by Oil-Red O staining. HEM inhibited the triglyceride accumulation of 3T3-L1 preadipocyte cell and reduced glycerol-3-phosphate dehydrogenase (GPDH) activity. We further investigated the effect of HEM in prevention of obesity in male ICR mouse for 5 weeks. Experimental groups were divided into high fat diet group (HFD), HFD supplemented with 100 mg/kg HEM group (HEM1) and HFD supplemented with 200 mg/kg HEM group (HEM2). Body weight and food efficiency ration of HEM1 and HEM2 was decreased by 52% and 50% and by 45% and 50%, respectively. The amount of adipocyte in body weight was decreased. Blood triglyceride and total cholesterol of HEM1 was significantly decreased. These results indicate that HEM may be useful in preventing obesity.

• Archives of Pharmacal Research
• /
• v.27 no.7
• /
• pp.790-796
• /
• 2004

Ginseng is a shade-loving perennial herb that is cultivated mainly in Korea, Japan, and China. The ginseng root has been used as a tonic remedy, and its antidiabetic activity has been demonstrated as early as 1920s. Although wild ginseng was anecdotally thought to be superior to cultivated ginseng as far as pharmacological properties were concerned, there have been no prior reports on the antidiabetic effect of wild ginseng. In this study, we investigated the preventative anti-diabetic and anti-obese effects of wild ginseng ethanol extract (WGEE). In the preventive experiment, WGEE co-administered with a high fat diet significantly inhibited body weight gain, fasting blood glucose, triglyceride, and free fatty acid levels in a dose dependent manner. WGEE-treated mice at doses of 250 and 500 mg/kg improved the insulin resistance index by 55％ and 61％ compared to the high fat diet (HFD) control, respectively. Diameters of white and brown adipocytes were also decreased by 62％ and 46％ in the WG500-treated group compared to those in HFD fed control mice. Taken together, WGEE has potential as a preventive agent for type 2 diabetes mellitus (and possibly obesity) and deserves clinical trial in the near future.